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Abstract
BACKGROUND: Randomized trials have demonstrated that the efficacy of anti-TNF agents is
significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA). In clinical
routine, anti-TNF agents are commonly prescribed with other disease modifying antirheumatic drugs
(DMARDs) than MTX, however their effectiveness in combination with anti-TNF agents is not well
established. OBJECTIVE: To compare the effectiveness of leflunomide (LEF) and other conventional
DMARDs with MTX as co-therapy to anti-TNF agents in RA. METHODS: All patients on anti-TNF
agents and conventional DMARDs within the SCQM-RA database were included (N=1218) and
categorized according to the type of co-therapy into anti-TNF+MTX (N=842), anti-TNF+LEF (N=260)
and anti-TNF+other DMARDs (N=116). Drug discontinuation rates and incidence of toxic side effects
were analyzed using Cox proportional hazards models. Progression of radiographic damage, the
evolution of functional disability and the improvement of RA disease activity were analyzed using
longitudinal regression models, adjusting for potential confounders. RESULTS: The overall
discontinuation rates of anti-TNF and conventional DMARD combination therapies were relatively high
with a median survival of only 16 months (IQR: 10 - 37), but they did not differ between the three
regimen (p=0.69). The progression of radiographic damage (p=0.77), functional disability (p=0.09) and
RA disease activity (p=0.33) were also similar between the different regimen. In addition, no significant
difference in the frequency of adverse events emerged. CONCLUSION: Overall these results suggest
that LEF and potentially other conventional DMARDs offer an effective and safe alternative to MTX as
co-therapy in combination with anti-TNF agents.
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Abstract: 
Background: Randomized trials have demonstrated that the efficacy of anti-TNF agents is 
significantly increased by concomitant methotrexate (MTX) in rheumatoid arthritis (RA). In 
clinical routine, anti-TNF agents are commonly prescribed with other disease modifying 
antirheumatic drugs (DMARDs) than MTX, however their effectiveness in combination with 
anti-TNF agents is not well established. 
Objective: To compare the effectiveness of leflunomide (LEF) and other conventional 
DMARDs with MTX as co-therapy to anti-TNF agents in RA. 
Methods: All patients on anti-TNF agents and conventional DMARDs within the SCQM-RA 
database were included (N=1218) and categorized according to the type of co-therapy into 
anti-TNF+MTX (N=842), anti-TNF+LEF (N=260) and anti-TNF+other DMARDs (N=116). 
Drug discontinuation rates and incidence of toxic side effects were analyzed using Cox 
proportional hazards models. Progression of radiographic damage, the evolution of functional 
disability and the improvement of RA disease activity were analyzed using longitudinal 
regression models, adjusting for potential confounders. 
Results:  The overall discontinuation rates of anti-TNF and conventional DMARD 
combination therapies were relatively high with a median survival of only 16 months (IQR: 
10 – 37), but they did not differ between the three regimen (p=0.69). The progression of 
radiographic damage (p=0.77), functional disability (p=0.09) and RA disease activity 
(p=0.33) were also similar between the different regimen. In addition, no significant 
difference in the frequency of adverse events emerged. 
Conclusion:  Overall these results suggest that LEF and potentially other conventional 
DMARDs offer an effective and safe alternative to MTX as co-therapy in combination with 
anti-TNF agents. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to 
progressive joint destruction, functional disability and extra-articular complications. New 
biologic disease modifying anti-rheumatic drugs (DMARDs) became available in 1999, 
including agents targeting tumor necrosis factor α (anti-TNF agents). Among these, 
infliximab (INF), etanercept (ETN) and adalimumab (ADA) have been shown to reduce signs 
and symptoms of RA and to protect joints from structural damage in randomized double-blind 
placebo-controlled trials (RCT). Certain anti-TNF agents can be prescribed alone, but 
randomized trials have consistently demonstrated that the efficacy of these biologic agents is 
significantly increased by concomitant methotrexate (MTX).[1] However, not all patients 
tolerate or respond to MTX and anti-TNF agents are commonly prescribed with other 
DMARDs than MTX in clinical routine.[2] Nevertheless, the effectiveness of non-MTX 
DMARDs as co-therapy with anti-TNF agents is not well established. The efficacy and safety 
of the combination of ETN and sulphasalazine as compared to either drug alone has been 
reported in a RCT of patients with incomplete response to sulphasalazine. The results 
demonstrated that the efficacy was similar in both groups treated with ETN, but superior to 
patients receiving sulphasalazine alone[3] Safety data were not significantly different in 
patients treated with the combination as compared to ETN alone.  
One of the most commonly prescribed concomitant DMARD with anti-TNF agents is 
Leflunomide (LEF).[4, 5] LEF is a pyrimidine synthesis inhibitor with immunomodulatory 
properties and anti-inflammatory activity, which has demonstrated its efficacy as a disease 
modifying drug (DMARD).[6] Several smaller retrospective case series have concluded that 
LEF in combination with anti-TNF agents appears to be effective and safe with appropriate 
monitoring.[7-11] Prospective case series and cohort studies have generally confirmed the 
efficacy of this combination.[12-14] In contrast, a short clinical trial of adalimumab and 
conventional DMARDs suggested that the efficacy of the combination with LEF was slightly 
lower than the combination with MTX and the incidence of serious adverse events slightly 
higher.[15, 16] Overall, there is currently no evidence from controlled trials that anti-TNF 
combinations with LEF are as effective as anti-TNF combinations with MTX. The objective 
of this study was thus to compare retention rates, effectiveness and safety of therapeutic 
regimen associating anti-TNF agents and LEF, MTX or other conventional DMARDs in a 
large population-based RA cohort. 
Patients and Methods 
Study population. Regulatory authorities in Switzerland have recommended 
continuous monitoring of all patients receiving biologic agents for arthritides and selected the 
SCQM system to follow RA patients put on anti-TNF agents [17]. Patients are generally 
enrolled prior to the initiation of anti-TNF therapy. The SCQM system mandates annual 
measurements of disease activity, radiographic damage, side effects and various symptom 
questionnaires [17]. Clinical information is updated every time the patient’s disease status 
requires a change of their antirheumatic therapy. The patient’s rheumatologist or primary care 
physician are incited to enrol their patient in the SCQM by allowing them to deduct costs of 
anti-TNF drugs from their global treatment expenditure scrutinized by the health authorities, 
which contributes to a high enrolment rate.[18] Patients come from a range of clinical settings 
with 50% from private practices, 25% non-academic centers and 25% coming from academic 
centers. The accuracy of medication data provided by the physicians - including anti-TNF 
start and stop dates - was confirmed against participants’ self-reported information and an 
additional assessment with the treating rheumatologist. 
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Study design. This is a longitudinal observational study of a population-based cohort 
of RA patients. The analysis included data collected between March 1996 through December 
2006. The inclusion criteria included a diagnosis of RA by a rheumatologist, treatment with 
INF, ETN or ADA. The exclusion criteria were the absence of concomitant DMARD therapy, 
and the simultaneous prescription of LEF and MTX in combination with anti-TNF agents, 
because the primary objective of this study was to study patients on either LEF, MTX or other 
DMARDs. 
Outcomes. We considered four outcomes that operationally define effectiveness: the 
overall retention rate of the current combination of anti-TNF agents and conventional 
DMARDs, the progression of long-term radiographic damage, the evolution of functional 
disability and the improvement of RA disease activity. 
We examined drug retention of current combination of anti-TNF agents and 
conventional DMARDs using the time until drug discontinuation, independently of the reason 
that led to drug interruption. Drug discontinuation rates or ‘drug survival rates’ reflect both 
the patients’ and doctors’ satisfaction with a given therapy and thus represent a useful 
summary measure of the overall treatment effectiveness and tolerability [19, 20]. Drug 
interruption was defined as the discontinuation of the current therapeutic combination, i.e. the 
interruption of either the anti-TNF agent or the concomitant DMARD or both. Temporary 
interruptions (less than 6 months) were not considered a discontinuation, neither were 
treatment interruptions for remission. 
A second end point was the progression of radiographic joint damage as measured by 
changes from baseline in radiographic damage scores. Radiographic damage was assessed 
prospectively by a single assessor on serial radiographs with a validated scoring system 
(Ratingen Score) according to a published method [21]. The scoring method is sensitive to 
change and less susceptible to ceiling effects in advanced disease because of a true ordinal 
rating scheme [22]. The reliability of this scoring method is excellent with an intraclass 
correlation coefficient (ICC) for intra-rater reliability of 0.8 to 0.9 and an ICC for inter-rater 
reliability of 0.7 to 0.9 [14, 21]. The minimal detectable radiographic change for this method 
has been determined to be 3.3% of the maximum score [21]. The intra-rater reliability for the 
study assessor of these radiographs was good with an intraclass correlation coefficient (ICC) 
of 0.94 for a cross-sectional assessment and an ICC of 0.71 for change scores. Sporadic 
missing joints in follow-up radiographs due to poor positioning were scored conservatively as 
unchanged using the ‘last observation carried forward’ procedure. 
Another outcome of this study was the progression of functional disability as 
measured by change from baseline in the Stanford Health Assessment Questionnaire 
disability index (HAQ) (10). The HAQ is a 20 item self-report questionnaire ranging from 0 
to 3, which tends to increase slowly over time in RA (average of 0.03 units per year [23]). 
The HAQ is the most widely used functional status questionnaire in rheumatology and has 
been shown to predict work disability [24], joint replacement [24], medical costs [25] and 
mortality [26] in RA.  
Finally, we examined RA disease activity using the Disease Activity Score (DAS28) 
[27]. The DAS28 is a validated physician assessment of disease activity in RA, which 
includes number of swollen joints, the number of tender joints and the erythrocyte 
sedimentation rate [27]. DAS28 ranges from zero to 9.2, where 9.2 represents maximum 
disease activity.  
A secondary outcome was the tolerability and side effects profile of the conventional 
DMARD co-therapies. Other important predictors of RA disease progression such as 
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measures of disease activity, self-assessed symptom questionnaires, various disease 
characteristics, and demographic characteristics, were extracted from the database to be used 
in the analysis.  
Exposure variables. The exposure of interest for this study was the type of 
conventional DMARD used in combination with anti-TNF agents. All patients treated with 
anti-TNF were thus categorized as MTX co-therapy (aTNF + MTX), LEF co-therapy (aTNF 
+ LEF), or other DMARD co-therapy (aTNF + other DMARD). Other DMARD co-therapy 
included sulfasalazine, hydroxychloroquine, minocycline, azathioprine, cyclosporine A, D-
penicillamine, oral or intramuscular gold salts. Concomitant glucocorticoid intake was 
considered separately. We excluded a priori patient on anti-TNF agents without conventional 
DMARD co-therapy, because it is well established that anti-TNF therapy is more effective in 
combination with these agents;[1, 4] therefore it is likely that patients on anti-TNF 
monotherapy have a more benign form of the disease or a history of more adverse reactions 
on conventional DMARDs, which might have biased the results if included (selection bias).  
Analysis. Baseline disease characteristics were compared between the three treatment 
strategies. The significance of differences in mean values of continuous variables was 
assessed with one-way analysis of variance (ANOVA) for normally distributed variables and 
with the Kruskal-Wallis test for non-normally distributed variables to test if at least one mean 
was significantly different from the others. For dichotomous variables, Pearson’s Chi-square 
test was used to evaluate the statistical significance of differences in proportions. All 
statistical tests were two-sided and evaluated at the 0.05 significance level. The statistical 
analysis was performed with Stata version 9.2 for Windows (Stata Statistical Software, Texas, 
USA).  
Confounding was a concern in this study, because the choice of DMARD co-therapy 
could be associated with disease severity or treatment tolerability. Because such an 
association may substantially influence disease progression, we used multivariate adjustments 
to overcome such confounding effects. The time to discontinuation of anti-TNF combination 
regimen was analyzed using a Cox proportional hazards model [28]. Survival curves of the 
time to discontinuation (‘drug survival’) were produced with the Kaplan-Meier product-limit 
method [28]. Radiographic damage, functional disability, and RA disease activity evolution 
were analyzed using generalized mixed models for longitudinal data [29]. We first selected 
the best fitting model without controlling for potential confounders (crude model). We 
verified that the multivariate normal assumption for longitudinal models was satisfied and 
examined whether time as a linear trend or as a polynomial function fit the data best. We then 
adjusted the analysis for differences in baseline disease characteristics. Rheumatoid factor, 
age, sex, disease duration, number of previous DMARD, type of anti-TNF agent, previous 
anti-TNF failure were all considered confounders a priori and added into the model. We 
tested other covariates using a backwards stepwise selection approach. The final model was 
adjusted for differences in disease activity (DAS28), functional disability (HAQ), 
glucocorticoids use, presence of rheumatoid factor, gender, age, disease duration, number of 
previous DMARD, type of anti-TNF agent and previous anti-TNF failure. Point estimates of 
the regression model were used to produce the result graphs. Pair-wise comparisons between 
the 3 treatment groups were planned a priori, but were considered only if the overall 
comparison indicated a significant difference (ANOVA, p < 0.05). To maintain a Type I error 
at 5%, pair-wise comparisons and confidence intervals of therapeutic groups were corrected 
with Bonferroni’s adjustment procedure.  
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Results 
A total of 1218 RA patients met the study inclusion criteria out of a total 2097 patients 
in the SCQM databank given anti-TNF agents. We excluded patients on anti-TNF agents 
alone, without concomitant DMARDs (843 patients) in order to minimize potential selection 
biases. We further excluded 36 patients who received simultaneously MTX, LEF and an anti-
TNF agent. The 1218 patients had an average of three follow-up assessments (IQR: 2 – 4) and 
a follow-up period of 17 months. The majority of patients used MTX as co-therapy with anti-
TNF agents (N=842, 69%); the second most common conventional DMARD used in 
combination with anti-TNF agents was LEF (N=260, 21%); other conventional DMARDs 
were prescribed infrequently (N=116, 10%). The median dose of MTX at baseline was 15 
mg/week (IQR: 10 – 20 mg/week) and the median dose of LEF at baseline was 20 mg/day 
(IQR (20 – 20 mg/day). The other conventional DMARD group was comprised of 
sulfasalzine (N=37, 32%), azathioprine (N=28, 24%), hydroxychloroquine (N=21, 18%), 
cyclosporine (N=7, 6%), injectable gold salts (N=4, 3%), penicillamine (N=3, 3%) and 
combinations of the above (N=16, 14%). No significant differences were found for baseline 
disease characteristics between treatment groups (Table 1). However, treatment characteristics 
differed somewhat between these groups, with for example MTX being combined more 
commonly with INF than with other anti-TNF agents (36% versus 27%, p = 0.01) and LEF 
and other DMARDs having a history of more prior failures on conventional DMARDs than 
MTX (median of 2 versus 1, p < 0.001). Furthermore, low dose glucocorticoids were used 
more frequently in combination in the other DMARD group compared to the MTX and LEF 
groups (67% versus 48-51%, p> 0.001). 
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Table 1:  Baseline characteristics of patients at initiation of anti-TNF therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease characteristics * Anti-TNF agents 
with MTX 
(N=842) 
Anti-TNF agents 
with LEF 
(N = 260) 
Anti-TNF agents 
with other DMARDs  
(N = 116) 
p °  
Age [years] 53 (14) 53 (13) 55 (15) 0.23 
Disease duration, median [yr]  8.4 
(IQR: 3.7 – 14.9) 
8.9  
(IQR: 3.3 – 14.2) 
9.9  
(IQR: 4.4-15.8) 
0.14 
Female [%] 76 79 78 0.57 
Rheumatoid factor positive [%] 80 83 83 0.60 
Disease Activity Score (DAS28) 4.1 (1.5) 4.5 (1.4) 4.6 (1.4) 0.31 
RA Disease Activity Index (RADAI) 4.3 (2.1) 4.5 (2.2) 4.2 (2.1) 0.43 
Functional disability (HAQ) 1.24 (0.71) 1.34 (0.67) 1.33 (0.72) 0.54 
Erosion score, median [% of max.]* 6.3  
(IQR: 2.0 – 17.3) 
5.8  
(IQR: 2.1 – 17.6) 
6.3 
(IQR: 2.7 – 17.3) 
0.85 
Type of Anti-TNF  
- Adalimumab [%] 
- Etanercept [%]  
- Infliximab [%] 
 
33 
31 
36 
 
41 
32 
27 
 
28 
45 
27 
 
0.02 
0.01 
0.01 
Previous anti-TNF failure, ever [%] 33% 41% 36% 0.06 
Concomitant steroid-use, ever [%] 48% 51% 67% 0.001 
N° of previous DMARDs, median [N] 1  (IQR: 0 – 2) 2  (IQR: 1 – 3) 2  (IQR: 1 – 3) < 0.001 
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Legend Table 1: 
* Values are given in mean ± standard deviations if not indicated otherwise. When not 
normally distributed, variable’s medians and interquartile ranges (IQR) are reported. ° One-
way analysis of variance (ANOVA) of means normally distributed continuous variables; 
Kruskal-Wallis test for non-normally distributed variables; Chi square test for dichotomous 
variables. Steroid use = concomitant use of oral glucocorticoids at any time during anti-TNF 
therapy; Erosion score based on the Ratingen scoring method = semi-quantitative scale 
estimating the proportion of destroyed joint surface in 38 hands and feet joints, expressed as 
percent of maximum score. * The total number of patients with a full set of radiographs 
available for scoring at baseline was lower: N = 859 instead of N=1218 ; DAS28 = Disease 
Activity Score based on 28 joints, higher scores indicate more disease activity; RADAI  = 
Rheumatoid Arthritis Disease Activity Index, higher scores indicate more disease activity; 
HAQ  = Health Assessment Questionnaire; higher scores indicate more disability. 
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Discontinuation of therapy. The discontinuation rates did not differ significantly between 
the three combinations of conventional DMARDs and anti-TNF agents (adjusted ANOVA, p = 
0.69) (Figure 1). A total of 1410 patient-years of combination therapy and 629 cases of treatment 
interruption were examined. The overall discontinuation rate of these combinations was relatively 
high with a median survival of only 16 months (IQR: 10 – 37), which is significantly higher than 
the discontinuation rate of the individual anti-TNF agents (median survival 31.5 months (IQR: 12 
– 68). The adjusted hazard ratio (HR) of discontinuing therapy was 1.08 (99% CI: 0.82 – 1.42) 
for the combination of LEF and anti-TNF agents compared to the other combinations, 0.92 (99% 
CI: 0.72 – 1.17) for MTX, and 1.06 (99% CI: 0.71 – 1.59) for other DMARDs. The unadjusted 
Cox proportional hazard model did display a lower discontinuation rate for the combination of 
anti-TNF and MTX (HR 0.79, 99% CI 0.63 – 0.99, crude ANOVA: p = 0.02), which completely 
disappeared when adjusted for the number of prior DMARDs and prior failures with anti-TNF 
agents, suggesting that these variables partially confounded the crude results. As expected, prior 
failure on another anti-TNF agent increased the rate of drug discontinuation (HR: 1.74, 95% CI: 
1.59 - 1.90). Other significant predictors of discontinuation were increased disease activity at 
baseline as measured by the DAS28 (HR: 1.09, 95% CI: 1.03 – 1.16) and shorter disease 
durations (HR: = 0.98, 95% CI: 0.97 – 0.99).  
Therapeutic effectiveness on RA disease progression. We did not find significant 
differences between the three combinations of conventional DMARDs and anti-TNF in 
radiographic damage progression (adjusted ANOVA: p = 0.77, Figure 2A), functional disability 
progression (HAQ) (adjusted ANOVA: p = 0.09, Figure 2B), or evolution of RA disease activity 
(DAS28) over time (adjusted ANOVA: p = 0.33, Figure 2C). The unadjusted analyses displayed 
very similar results.  
Overall, radiographic damage progressed only insignificantly with all three therapeutic 
combinations (Figure 2A): Patients on anti-TNF + MTX progressed on average by 0.91% (99% 
CI: 0.54 – 1.27), patients on anti-TNF + LEF by 0.74% (99% CI: 0.21 – 1.27) and patients on 
anti-TNF + other DMARDs by 0.71% (99% CI: -0.02 – 1.44) of the maximum possible erosion 
score at one year. Significant predictors for increased radiographic progression were elevated 
functional disability at baseline as measured by the HAQ (p < 0.001), recent disease onset (p < 
0.001), older age (p = 0.004) and numerous failures on previous DMARDs (p < 0.001). 
Functional disability generally improved during the first and second year after initiation of 
the combination of anti-TNF agents and conventional DMARDs (Figure 2B) and the therapeutic 
response was similar with all three combinations. After one year, HAQ scores improved by 0.12 
(99% CI: 0.08 – 0.15) with anti-TNF + MTX, by 0.14 (99% CI: 0.07 – 0.20) with anti-TNF + 
LEF, and by 0.13 (99% CI: 0.03 – 0.23) with anti-TNF + other DMARDs. Significant predictors 
for functional disability improvement were younger age (p < 0.001), male gender (p < 0.001), 
recent disease onset (p < 0.001), lower disease activity at baseline as measured by the DAS28 (p 
< 0.001), less failures on previous DMARDs (p < 0.001) and no need for concomitant 
glucocorticoids (p < 0.001). 
The level of improvement in disease activity also varied little between the three groups: 
DAS28 improved by 0.74 (99% CI: 0.63 - 0.84) with anti-TNF + MTX, by 0.63 (99% CI: 0.45 - 
0.82) with aTNF + LEF and by 0.86 (99% CI: 0.60 - 1.12) with anti-TNF + other DMARDs 
during the first year after treatment initiation. Depending on the absolute level of disease activity, 
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DAS28 improvements between 0.6 and 1.2 are considered moderate therapeutic responses and 
improvements greater than 1.2 are considered good therapeutic responses (EULAR response 
criteria) [30]. Overall, 62% of all patients receiving anti-TNF agents in combination with 
conventional DMARDs were considered responders after 1 year, 19% as having a good response 
and 44.5 % as having moderate response. The proportion of good and moderate responders did 
not differ significantly between the 3 groups (p=0.06) after correcting for differences in baseline 
covariates. Significant predictors greater improvements in disease activity after treatment 
initiation were younger age (p < 0.001), male gender (p < 0.006), lower functional disability at 
baseline as measured by the HAQ (p < 0.001), negative of rheumatoid factor (p=0.001), no need 
for concomitant glucocorticoids (p < 0.001) and no prior failure on prior anti-TNF agent (p = 
0.01).  
Tolerability and Safety. One hundred and seventy eight combination therapies were 
interrupted because of adverse events (28%). The most common adverse events leading to 
treatment interruption were allergic reactions (28%), infections (19%), skin reactions (19%), and 
gastro-intestinal side effects (12%). Hepatotoxicity (2%) and malignancies (6%) were rare causes 
of treatment interruption in this cohort. We found no difference between the three combinations 
of conventional DMARDs and anti-TNF agents in the overall incidence of side effects (ANOVA, 
p = 0.13), nor in time to the occurrence of side effects (ANOVA, p = 0.24). Furthermore, we did 
not find significant differences between these combinations in the specific types of adverse 
events, with the exception of allergic complication that were reported slightly less often with the 
combination anti-TNF + MTX (HR: 0.45, 98% CI: 0.20 – 0.98) than with the other two 
combinations (ANOVA, p = 0.04). In particular, no trend for an increasing incidence of 
dermatological adverse events was found with the combination anti-TNF + LEF, (ANOVA, p = 
0.18), which had been previously described.[5, 12] However, the total numbers of events for the 
specific side effects were low. 
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Discussion:  
We studied the effectiveness and safety of the combination of anti-TNF + LEF as compared 
to the combination of anti-TNF + MTX and anti-TNF + other DMARDs in a population-based 
cohort of 1281 patients with RA. The overall discontinuation rates of these combinations were 
relatively high with a median survival of only 16 months (IQR: 10 – 37), but the discontinuation 
rates did not differ between the three regimen. The retention of the individual anti-TNF agents 
was significantly longer (median survival of 31.5 months (IQR: 12 – 68)) suggesting that 
physicians confronted with inadequate therapeutic responses or side effects attempt first to 
modify the co-therapy with conventional DMARDs, before eventually changing the anti-TNF 
agent. The progression of structural joint damage (radiographic erosion score), functional 
disability (HAQ) and RA disease activity (DAS28) were also similar in the different regimen. In 
addition, the analysis of side effects did not show any significant differences regarding the 
frequency and type of adverse events. Overall these results suggest that LEF and other 
conventional DMARDs can offer an effective and safe alternative to MTX as a co-therapy in 
combination with anti-TNF agents. 
In this cohort, 21% of all patients on anti-TNF combination therapy had LEF as co-therapy, 
which appears to be higher than published figures from other registries (9% - 13%).[5, 31] This is 
probably explained by habits of local rheumatologists and the relatively long disease durations of 
patients enrolled in the SCQM, which often have a history of prior treatment failure on MTX. 
Most published reports on the combination of anti-TNF agents and LEF are based on 
retrospective case series [5, 7-11] and lack a control groups, which does not permit comparisons 
with other conventional DMARD combinations such as aTNF + MTX. One prospective cohort 
study assessed INF in combination with conventional DMARDs and confirmed clinical responses 
and incidence of adverse events were not different in patients treated with LEF as compared to 
other conventional DMARDs.[14] However, groups were relatively small (LEF group: N=33) 
limiting the statistical power to reveal small differences. Interestingly, the median drug survival 
of the INF – LEF combination was also relatively short (9 months) and drug retention rates were 
also similar between the different conventional DMARD groups. Other studies have reported 
more conflicting results. More patients withdrew INF in combination with LEF than in 
combination with MTX due to adverse events and severe infusion reactions.[32] Different 
combinations of ADA with DMARDs were examined in a recent 12-week open-label multicenter 
prospective study. The effectiveness of ADA and LEF was lower than ADA and MTX, with 
significantly fewer patients achieving ACR or EULAR responses.[15] In addition, the rate of 
serious adverse events and serious infections were also higher among patients treated with LEF 
as compared to MTX (8.2% vs 4.6% and 1.1% vs 1.9%, respectively).[15]  
In this study, the reason for discontinuing the combination of anti-TNF and conventional 
DMARDs was an adverse event in approximately one third of all treatment interruptions, the 
remainder being justified by treatment inefficacy, patient preferences, remission or low disease 
activity, pregnancies and other non-toxic causes. These findings are in line with other reports,[14] 
but the incidence of adverse events was lower than some older studies.[9, 12] This apparent 
discrepancy could be partially explained by the fact that adverse events tend to be reported only if 
considered clinically important by physicians. The perception of what side effect is clinically 
relevant might have changed in recent years, as rheumatologist are more used to manage biologic 
therapies. Furthermore, we analyzed only the adverse events that led to treatment discontinuation. 
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This analysis has potential limitations inherent to the analysis of observational data. We 
had no control over the treatment assignment of MTX versus LEF or other concomitant 
DMARDs, which could result in selection bias or confounding by indication. Because no 
rationale exists for favoring one concomitant DMARD over the other in terms of efficacy, 
substantial confounding by indication between these groups is unlikely. Confounding by 
indication is more likely for anti-TNF agents prescribed with or without concomitant DMARDs, 
which is why we restricted our analysis to only patients receiving anti-TNF agents in 
combination with conventional DMARD therapy. We found no significant differences in disease 
characteristics and common predictors of disease progression between the 3 treatment groups. 
However, as expected, certain treatment characteristics differed between these groups. While we 
could adjust our analysis for many important disease and treatment characteristics potentially 
associated with disease progression, we cannot exclude the possibility of residual confounding or 
confounding by unmeasured factors.  
Concomitant DMARD therapy was defined at anti-TNF therapy initiation; all patients 
started concomitantly on traditional DMARDs were analyzed as such, whether they continued 
treatment or not. In clinical practice, concomitant therapy with traditional DMARDs is a dynamic 
process that might not be captured completely with this definition. This is, however, a 
conservative approach, comparable to an ‘intention to treat’ analysis in randomized trials, which 
tends to underestimate the true treatment effect. Because the discontinuation rates of these 
combinations were similar, it is unlikely that drug retention substantially biased the comparison 
of therapeutic effectiveness between the three antirheumatic regimen. The present analysis 
offered sufficient power to detect small differences in effectiveness or retention rates between 
MTX and LEF in combination with anti-TNF agents. However, the ‘other DMARD’ group was 
relatively small (N=116) and heterogeneous (including both cytotoxic and noncytotoxic agents), 
limiting the strength of the conclusions regarding this therapeutic group.  
Missing data is another concern with observational studies. In particular, only 84% of all 
patients had radiographic data for the analysis of radiographic damage progression. Baseline 
disease characteristics of patients without available radiographs were similar to those included in 
the present analysis suggesting that the study’s inclusion criteria selected a representative sample 
of the population. Strengths of this analysis include a true population-based cohort due to the fact 
that the Swiss authorities recommended enrolment of all patients receiving anti-TNF agents, a 
systematic prospective ascertainment of a wide variety of potential confounders and longitudinal 
radiographic data. 
In this large population-based cohort, we found no difference in drug discontinuation rates 
or in effectiveness measures between anti-TNF + MTX, anti-TNF + LEF and anti-TNF + other 
DMARD. Furthermore, the safety data of the combinations of anti-TNF + LEF and anti-TNF + 
other DMARD are reassuring and show that these combinations are well tolerated. Taken 
together, these results suggest that LEF and potentially other DMARDs offer an effective and 
safe alternative to MTX as cotherapy in combination with anti-TNF agents. 
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Figure 1:  Retention rates of different combinations of anti-TNF agents and conventional DMARDs 
The Kaplan-Meier curve for time to discontinuation of three combinations of anti-TNF agents 
and conventional DMARDs (‘drug survival’). Survivor curve was adjusted for baseline disease 
activity (DAS28), baseline functional disability (HAQ), presence of rheumatoid factor, gender, 
age, disease duration, number of previous DMARD, previous anti-TNF failure, type of anti-TNF 
agent and glucocorticoids. LEF = leflunomide; MTX= methotrexate; other DMARD = 
sulfasalazine, hydroxychloroquine, minocycline, azathioprine, cyclosporine, D-penicillamine, 
oral or intramuscular gold salts. 
Figure 2:   Progression of radiographic joint damage (A) functional disability (B) and RA disease 
activity (C) after initiation of an anti-TNF agents and a conventional DMARD 
aTNF + MTX = anti-TNF agent with concomitant Methotrexate;  aTNF + LEF = anti-TNF 
agent with concomitant leflunomide; aTNF + other DMARD = anti-TNF agent with other 
concomitant disease modifying antirheumatic drug (sulfasalazine, hydroxychloroquine, 
minocycline, azathioprine, cyclosporine, D-penicillamine, oral or intramuscular gold salts). 
Figure 2A represents radiographic joint damage progression (=ERO) over time for the average 
time on treatment. The vertical lines represent the 99% confidence interval of the mean. ERO 
score [%] represents the percentage of maximum possible damage of the Ratingen erosion score 
and corresponds to the average proportion of joint surface damaged by erosions. The progression 
trajectories depicted are adjusted for differences in baseline disease activity (DAS28), functional 
disability (HAQ), glucocorticoids use, presence of rheumatoid factor, gender, age, disease 
duration, number of previous DMARD, type of anti-TNF agent and previous anti-TNF failure 
(=adjusted model). 
Figure 2B represents progression of functional disability (=HAQ) over time. The vertical lines 
represent the 99% confidence interval of the mean. HAQ score from the Stanford Health 
Assessment Questionnaire ranges from 0 to 3, where 3 represents the maximum possible 
disability. The progression trajectories depicted are adjusted for differences in baseline disease 
activity (DAS28), glucocorticoids use, presence of rheumatoid factor, gender, age, disease 
duration, number of previous DMARD, type of anti-TNF agent and previous anti-TNF failure. 
(=adjusted model). 
Figure 2C represents the evolution of RA disease activity (=DAS28) over time. The vertical lines 
represent the 99% confidence interval of the mean. The DAS28 ranges from 0 to 10, where 10 
represents the maximum possible activity. The progression trajectories depicted are adjusted for 
differences in baseline disease functional disability (HAQ), glucocorticoids use, presence of 
rheumatoid factor, gender, age, disease duration, number of previous DMARD, type of anti-TNF 
agent and previous anti-TNF failure. (=adjusted model).
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